ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib
NEWTOWN SQUARE, PA — ArriVent Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously …
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib Read More